Methotrexate-associated orbital lymphoproliferative disorder in a patient with rheumatoid arthritis: a case report
- 467 Downloads
Lymphoproliferative disorders (LPDs) can develop in patients treated with methotrexate (MTX) and usually respond well to MTX withdrawal. Mucosa-associated lymphoid tissue (MALT) lymphoma is a relatively rare type of MTX-LPD. The development of MTX-LPD in the orbit has not been previously described. We here report a case of orbital MALT lymphoma that disappeared after MTX withdrawal in a patient treated with MTX for rheumatoid arthritis.
A 78-year-old woman who complained of swelling of the left upper eyelid had been treated with MTX for >8 years for rheumatoid arthritis. Slit-lamp examination revealed a temporal subconjunctival mass, salmon pink in color, in the left eye. Fundus photographs also suggested the presence of a temporal tumor in the left orbit. [18F]Fluorodeoxyglucose positron emission tomography-computed tomography revealed highly integrated lesions in the left inferotemporal orbit and a left external iliac lymph node, a left obturator lymph node, and an inguinal lymph node. Pathologic analysis of a tumor biopsy specimen showed small- and medium-sized lymphocytes positive for CD20, MIB-1, and bcl-2 and negative for CD10, CD3, bcl-1, IgG4, and EBV-ISH. On the basis of these findings, we diagnosed the tumor as MTX-induced MALT lymphoma. The subconjunctival and orbital masses disappeared gradually over 10 months after MTX withdrawal and did not recur within 2 years.
This case of orbital MTX-LPD suggests that the possibility of MTX-LPD should be considered even for ocular tumors in patients treated with MTX.
KeywordsMethotrexate-associated lymphoproliferative disorder (MTX-LPD) Mucosa-associated lymphoid tissue (MALT) lymphoma Orbital lymphoma Malignant lymphoma Rheumatoid arthritis
Conflicts of interest
Y. Kobayashi, None; K. Kimura, None; Y. Fujitsu, None; K. Shinkawa, None; H. Muta, None; K. Sonoda, None.
- 1.Subcommittee on the Development of Guidelines for the Use of Methotrexate in the Treatment of Rheumatoid Arthritis. Medical guidelines for the use of methotrexate (MTX) in the management of rheumatoid arthritis [in Japanese, translated by author]. Tokyo, Japan: Yodosha; 2011.Google Scholar
- 3.Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of tumours: pathology & genetics of tumours of haematopoietic and lymphoid tissues. Paris: IARC Press; 2001.Google Scholar
- 5.Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013;91:20–8.CrossRefPubMedGoogle Scholar
- 6.Kikuchi K, Ishige T, Ide F, Ito Y, Saito I, Hoshino M, et al. Overexpression of activation-induced cytidine deaminase in MTX- and age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorders of the head and neck. J Oncol. 2015;. doi: 10.1155/2015/605750.PubMedPubMedCentralGoogle Scholar
- 7.Felcht M, Booken N, Stroebel P, Goerdt S, Klemke CD. The value of molecular diagnostics in primary cutaneous B-cell lymphomas in the context of clinical findings, histology, and immunohistochemistry. J Am Acad Dermatol. 2011;64:135–43, 143.e1–4.Google Scholar
- 8.Goto H. Diagnosis and treatment of malignant ocular tumor. J Tokyo Med Univ. 2007;65:350–8.Google Scholar
- 9.Sumi T. Methotrexate (MTX)-associated lymphoproliferative disorders. J Otolaryngol Jpn. 2013;116:734–5.Google Scholar
- 17.Suzuki Y, Tanaka C, Ozaki S, Hotta T. The lymphoproliferative disorder caused by methotrexate (MTX). Rheumatology. 2002;28:498–506.Google Scholar
- 18.Harada K, Murakami N, Kitaguchi M, Sekii S, Takahashi K, Yoshio K, et al. Localized ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation therapy: a long-term outcome in 86 patients with 104 treated eyes. Int J Radiat Oncol Biol Phys. 2014;88:650–4.CrossRefPubMedGoogle Scholar
- 19.Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Paris: IARC Press; 2008.Google Scholar